Search PubMed⌕ Search

Biomedical subjects

F Bozzetti

Publications and source records attributed to F Bozzetti.

At least 145 records · Page 8Linked to original sources
PubMed1978

Protein loss after radical mastectomy as a cause of postoperative hypoalbuminemia.

The concentrations of serum albumin and the cumulative loss of albumin through the drainage tubes were followed in 14 patients who underwent radical mastectomy for cancer. The concentration of serum albumin declined during the postoperative period, and the nadir was on the 5th day. On the first 5 days a good correlation was observed between hypoalbuminemia and loss of albumin from the wound. After this period, hypoalbuminemia persisted unchanged although small quantities of albumin continued to be lost through the drains. It is concluded that in surgery complicated by abundant serum discharge, the albumin loss may be the main cause of postoperative hypoalbuminemia.

Breast Neoplasms↗
PubMed1978

Malignant pleural mesothelioma.

A series of 12 cases of mesothelioma is presented, and the data in the literature is reviewed in an attempt to formulate a program of treatment for this malignant, fast-growing and rapidly fatal tumor.

Adult↗
PubMed1978

Breast cancer in a patient under levodopa treatment.

A case history of a patient who developed mammary cancer (T1N1bMo) after 5 1/2 years of continuous treatment with Levodopa for Parkinson's disease is presented. The prolactin inhibition by the Levodopa was verified, and the clinical and mammographic growth, the doubling time, and the labeling index of the tumor were determined. The results were not significantly different than those obtained from patients with breast cancer not under treatment with Levodopa. The rapid growth and evolution of this tumor suggests that prolactin does not have an inducer or promoter effect in mammary cancer.

Adenocarcinoma↗
PubMed1976

Parenteral nutrition in surgical patients.

Nitrogen balance has been studied under conditions of simple fasting and in the postoperative period on a total of 102 patients. It is much more difficult to restore a positive nitrogen balance in the post-traumatic period, and this can be obtained only with calorie and, above all, amino acid quotas much higher than those capable of equilibrating the balance of fasting patients. The absence of a constant relationship between nitrogen sparing and the caloric value of the solutions infused and the advantages of hyperamino-acid therapy for the purpose of the balance agree with the hypothesis that the postoperative protein catabolism has the purpose of supplying the injured area with intermediate carbohydrate metabolites and constitutes the theoretic basis for the use of parenteral hyperalimentation during the postoperative period. This can be planned with doses of 35 to 40 calories per kilogram per day in the form of dextrose solution plus at least 2 grams of amino acids per kilogram per day.

Adult↗
PubMed1975

Parenteral hyperalimentation and wound healing.

In the first five postoperative days following abdominoperineal resection, two groups of five patients were treated by infusion therapy following two schedules: 11.9 calories per kilogram per day and 0.042 gram of nitrogen per kilogram per day, and 53.8 calories per kilogram per day and 0.244 gram of nitrogen per kilogram per day. Nitrogen balance was determined, and the wound collagen content was evaluated by biopsies carried out on the second, third, fourth, fifth, sixth, ninth, 12th and 15th postoperative days. It was noted that in group 2 patients nitrogen balance was rather equilibrated and the quantity of collagen in the granulation tissue was higher than in group 1. Postoperative parenteral hyperalimentation spares a good quantity of nitrogen and can facilitate wound healing.

Adult↗
PubMedDate not supplied

Regulatory relevance of lipoproteins in interleukin-2 stimulated lymphocytes in vitro.

The regulatory role of very low density lipoproteins (VLDL) in de novo protein synthesis and in natural killer (NK) mediated cytotoxicity against cancer cells was evaluated in IL-2 activated peripheral blood mononuclear cells (PBL). Supplementing of VLDL to the incubation medium induced a potent dose-related inhibitory effect on the synthesis and secretion of (35S) labelled proteins. The maximal inhibitory response was observed at 50 micrograms/ml cholesterol VLDL. The effect of VLDL on the IL-2 induced ability of lymphocytes to kill cancer cells and to interfere with target cell proliferation was then evaluated. Maximal cytotoxicity was observed at 50 micrograms VLDL/ml as cholesterol. This VLDL-dependent stimulatory effect was associated with a significant decrease in the proliferative effect of the medium conditioned by PBL. The possibility that VLDL mediate the regulation of immune functions by interacting with metabolic patterns expressed by IL-2 stimulated lymphocytes is discussed in light of these results.

Adult↗
PubMedDate not supplied

Percutaneous gastrostomy in oncologic patients: analysis of results and expansion of the indications.

BACKGROUND: Percutaneous gastrostomy is generally performed for permanent enteral nutrition or gastric decompression. METHODS: In our series of oncologic patients, percutaneous gastrostomy was also used temporarily in some patients for enteral nutrition while awaiting functional recovery of swallowing, in preparation for surgery, or for the treatment of fistulas in the upper digestive tract. Fifty-one procedures were performed in 50 patients: 42 for feeding, eight for decompression, and one for transgastric drainage of a duodenal fistula. RESULTS: Of the 35 patients treated for permanent enteral nutrition, four are still alive, with a total survival time of 2,167 days. In three patients, gastrostomy was performed for temporary feeding and was removed once the ability to swallow was restored. In four patients, it was created to restore metabolic balance before surgery. In the patient with a duodenal fistula, healing was achieved in 19 days. The seven patients in whom the procedure was performed for decompression survived for a mean of 19.2 days. There was only one major procedure-related complication (peritonitis). CONCLUSIONS: Percutaneous gastrostomy is a safe, low-cost method that allows the patient to maintain essential nutrition without the discomfort of a nasogastic tube and therefore warrants wider and earlier use. We feel that its application should also be extended to temporary feeding of patients about to undergo long courses of chemotherapy and radiotherapy, which can lead to severe deterioration of nutritional status.

Aged↗
PubMedDate not supplied

Effect of plasma from cancer patients on rat skeletal muscle protein degradation and PGE2 release in vitro.

Cachexia in tumour-bearing patients involves loss of skeletal muscle proteins. In order to elucidate the mechanisms underlying this phenomenon, we tested the hypothesis of the presence of a circulating proteolytic factor (possibly interleukin-1, acting through an increased PGE2 release) in the plasma of cancer patients, because such a mechanism has been demonstrated in patients with sepsis or trauma and in animals with bacteraemia or viraemia. The effect of plasma from 13 malnourished cancer patients and 14 controls on PGE2 release and protein degradation (assessed as Tyr release) in rat diaphragm in vitro was evaluated; human recombinant interleukin-1 alpha (IL-1) was used for comparison. IL-1 increased PGE2 release (+44% at 5 U/ml), but did not greatly affect proteolysis. On the contrary, human plasma (125 microliters/ml) from both control and tumour-bearing individuals did not affect PGE2 release significantly, but greatly reduced Tyr release. The decrease in Tyr release by plasma was dose-dependent. In conclusion, our data indicate that, at variance with what was demonstrated in patients with trauma or sepsis, loss of skeletal muscle proteins in cancer patients is not mediated by a circulating factor. In addition, evidence is provided of dissociation between PGE2 and Tyr release and of lack of proteolytic activity for IL-1.

Animals↗
PubMedDate not supplied

Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study.

The purpose of this study was to evaluate the efficacy of glutamine in preventing doxifluridine-induced diarrhea and the potential impact of glutamine on the tumor growth. We investigated 65 patients with advanced breast cancer receiving doxifluridine in a double-blind randomized fashion: 33 patients took glutamine (30 g/d, divided in 3 doses of 10 g each) for 8 consecutive days (5-12h) during each interval between chemotherapy, which was administered from day 1 to 4. Thirty-two patients took an equal dose of placebo (maltodextrine). The incidence of diarrhea was registered after each cycle of chemotherapy and severity was scored by the National Cancer Institute (NCI), Bethesda, Maryland, classification. The tumor response was evaluated by the World Health Organization (WHO) criteria. A total of 278 and 259 cycles (median 10 cycles), respectively, were delivered in glutamine and placebo groups. There were 34 and 32 episodes of diarrhea in glutamine and placebo groups, with no statistical difference overall, in the severity and duration of tumor growth, there was no difference in the response rate (21% and 28% of complete or partial response, respectively), in median time to response (2 mo), or in median duration of response. In conclusion, glutamine did not prevent the occurrence of the doxifluridine-induced diarrhea and did not have any impact on tumor response to chemotherapy.

Administration, Oral↗